Peter Breggin

Peter Roger Breggin was born on May 11, 1936, and is among the most credentialed figures in this database. He graduated with honors from Harvard College in 1958, earned his M.D. from Case Western Reserve School of Medicine, and completed psychiatric residency training at Harvard Medical School's Massachusetts Mental Health Center, where he was a teaching fellow. He subsequently served as a full-time consultant at the National Institute of Mental Health (NIMH) and held faculty appointments at the Washington School of Psychiatry, Johns Hopkins University Department of Counseling, and George Mason University. He has been in private psychiatric practice since 1968.

Breggin's early career included some genuinely valuable advocacy work: in the 1970s he helped block a federal government psychosurgery program targeting prisoners and minority groups, work that was recognized as important civil liberties advocacy. He founded the Center for the Study of Psychiatry in 1972, which has since been renamed the International Society for Ethical Psychology and Psychiatry. His concerns about the overuse of stimulants in children and the inadequate disclosure of psychiatric drug side effects touched on real problems within the field.

However, Breggin's positions hardened from 'psychiatric drugs are overused and their risks are underappreciated' to 'all psychiatric drugs are neurotoxins with no legitimate use.' His books including 'Toxic Psychiatry' (1991), 'Talking Back to Prozac' (1994), and 'Talking Back to Ritalin' (1998) became canonical texts for the anti-psychiatry movement and Scientology's Citizens Commission on Human Rights, and have been cited by people who stopped taking psychiatric medication without supervision with sometimes fatal results. Multiple courts have excluded his expert testimony on psychiatric drug effects as reflecting personal bias rather than scientific standards, with judges specifically noting that his opinions were not based on good science.

In his final career phase, Breggin has moved into COVID conspiracy territory, co-authoring with his wife Ginger the 2021 book 'COVID-19 and the Global Predators: We Are the Prey,' which describes COVID vaccines as bioweapons deployed by a 'global predator class.' He appeared on Alex Jones's InfoWars to promote these claims. His trajectory — from legitimate reformist critique to absolute rejection of an entire medical field, then to pandemic conspiracy theories — illustrates how the prestige of genuine credentials can carry a figure far beyond the territory where those credentials provide any actual expertise.

“All psychiatric drugs cause brain damage and their harms always outweigh any therapeutic benefit.”

While psychiatric medications carry real risks and have been overprescribed in some contexts — a legitimate concern — the absolute claim that no psychiatric drug provides net benefit to any patient is contradicted by extensive clinical trial evidence. Antipsychotics reduce hospitalization rates in schizophrenia; lithium reduces suicide risk in bipolar disorder; SSRIs show efficacy above placebo in

“COVID-19 vaccines are bioweapons developed by 'global predators' for depopulation and population control.”

COVID-19 vaccines were developed through standard pharmaceutical processes, evaluated in clinical trials involving tens of thousands of participants, and administered to billions of people with ongoing safety monitoring by independent regulatory agencies in dozens of countries. The 'bioweapon' and 'depopulation' claims are unsupported by any credible evidence and contradict the observed epidemiolo

“ADHD is not a real disorder and Ritalin is a harmful neurotoxin with no legitimate therapeutic use.”

ADHD is recognized as a neurodevelopmental disorder by every major psychiatric and neurological body globally, with a genetic component documented in twin studies and neuroimaging correlates in brain development research. Methylphenidate (Ritalin) has documented efficacy in improving attention and reducing functional impairment in ADHD across hundreds of randomized controlled trials. Concerns abou